In an ARDS mouse model, the MSC-mediated mechanism of CAP activation could increase the expression levels of choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) to alleviate ARDS-like syndrome.207 These results indicate that focusing on the CAP pathway is a potentially effective therapeutic strategy for treating ARDS and various other inflammatory lung diseases. The gene discussed is SLC18A3; the disease is acute respiratory distress syndrome.